Migraine Trial, Recruiting (NCT06603558)

Migraine Trial, Recruiting NCT06603558 Sponsor: AbbVie Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT06603558 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have migraines and whose condition is suitable for treatment with atogepant, based on the most current approved guidelines in their country.
People for whom a doctor has prescribed atogepant in line with the approved local guidelines.

Who may not be able to join:

People who have any medical reason that makes atogepant unsuitable or unsafe for them, as listed in the most current approved local guidelines.
People who are currently taking part in another clinical trial (note: participation in an observational study does not appear to be a barrier, but confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: +82-10-2230-3629

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06603558

Sponsor: AbbVie

Phase: Not Applicable

Status: Recruiting

Condition: Migraine

Trial contact: +82-10-2230-3629

More information: https://clinicaltrials.gov/study/NCT06603558

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have migraines and whose condition is suitable for treatment with atogepant, based on the most current approved guidelines in their country.
People for whom a doctor has prescribed atogepant in line with the approved local guidelines.

Who may not be able to join:

People who have any medical reason that makes atogepant unsuitable or unsafe for them, as listed in the most current approved local guidelines.
People who are currently taking part in another clinical trial (note: participation in an observational study does not appear to be a barrier, but confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AbbVie

Registry

ClinicalTrials.gov

Start date

24 September 2024

Est. completion

1 May 2029

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Percentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR); Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR); Percentage (%) of participants who reported known (labeled) ADR; Percentage (%) of participants who reported non-serious AE/ADR; Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the Risk Management Plan (RMP); Percentage (%) of participants with AE: overall summary; Percentage (%) of par...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov